Purpose of Review Severe-acute respiratory coronavirus 2 (SARS-CoV-2) has been driving the health care delivery system for over 2 years. With time, many issues related to co-infections in COVID-19 patients are constantly surfacing. There have been numerous reports about various fungal co-infections in patients with COVID-19. The extent of severity of fungal pathogens has been recognized as a substantial cause of morbidity and mortality in this population. Awareness, understanding, and a systematic approach to managing fungal co-infections in COVID-19 patients are important. No guidelines have enumerated the stepwise approach to managing the fungal infections co-occurring with COVID-19. This review is intended to present an overview of the fungal co-infections in COVID-19 patients and their stepwise screening and management. Recent Findings The most common fungal infections that have been reported to co-exist with COVID-19 are Candidemia, Aspergillosis, and Mucormycosis. Prevalence of co-infections in COVID-19 patients has been reported to be much higher in hospitalized COVID-19 patients, especially those in intensive care units. While clear pathogenetic mechanisms have not been delineated, COVID-19 patients are at a high risk of invasive fungal infections. Summary As secondary fungal infections have been challenging to treat in COVID-19 patients, as they tend to affect the critically ill or immunocompromised patients, a delay in diagnosis and treatment may be fatal. Antifungal drugs should be initiated with caution after carefully assessing the immune status of the patients, drug interactions, and adverse effects. The crucial factors in successfully treating fungal infections in COVID-19 patients are optimal diagnostic approach, routine screening, and timely initiation of antifungal therapy.

No abstract

Primary renal cell lymphoma is a rare type of non-Hodgkin’s lymphoma, with B-cell lymphoma being the most common subtype. Imaging and preoperative biopsy are fruitful ways to diagnose renal cell lymphoma. We report a rare case of primary renal cell lymphoma with bilateral renal involvement in a 52-year-old woman based on imaging findings, histopathology, and immunohistochemical markers. The patient is being treated with Rituximab, cyclophosphamide, adriamycin, vincristine, prednisolone, and intrathecal methotrexate. Furthermore, the present study also reviewed 22 cases of bilateral PRL that have been reported in this century to date. With this case report, we focus the spotlight on the fact that, though rare, the diagnosis of primary renal cell lymphoma still needs to be in the differential diagnosis of renal masses.